Search BTCY
BIOTRICITY INC.
OTC · CIK 1630113
Last close0.06
Daily change-0.00 (-0.00%)
10 Years gain-99.56%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BTCY · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 0331
Fundamental
62.4Momentum
100.0Acceleration
100.0Confidence
84.0Annual Revenue8
Quarterly Revenue32
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth21.6 / 25
Quality15.8 / 25
Capital Efficiency20.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 7.3135 percentage points.
Operating leverageOperating margin improved by 42.1664 percentage points.
Share count reductionDiluted share count declined 4.6879%.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Key Metrics
Revenue Growth TTM20.79%OK
Revenue CAGR 3Y18.4%OK
Gross Margin81.63%OK
Operating Margin7.21%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-4.69%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY Mar 31, 2026 | $16.00M | $12.95M | $1.69M | -$718,955.00 | n/a | 80.94% | 10.57% | n/a | n/a | 27.3M |
| 2026 FY Mar 31, 2025 | $13.79M | $10.56M | -$2.45M | -$2.38M | n/a | 76.61% | -17.76% | n/a | n/a | 21.52M |
| 2025 FY Mar 31, 2024 | $12.06M | $8.36M | -$8.83M | -$6.69M | n/a | 69.27% | -73.18% | n/a | n/a | 8.99M |
| 2024 FY Mar 31, 2023 | $9.64M | $5.44M | -$15.41M | -$13.55M | n/a | 56.46% | -159.87% | n/a | n/a | 8.66M |
| 2023 FY Mar 31, 2022 | $7.65M | $4.57M | -$16.74M | -$15.16M | -$15.19M | 59.74% | -218.77% | -198.6% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $16.02M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-039209, 0001493152-25-023361 |
| Revenue Growth TTM | 20.79% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-039209, 0001493152-25-023361 |
| Revenue CAGR 3Y | 18.4% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-033207 |
| Revenue CAGR 5Y | 36.43% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-033207 |
| Gross Profit CAGR 3Y | 33.5% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-033207 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-039209, 0001493152-25-023361 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 81.63% | Gross Profit / Revenue | OK | 0001493152-26-039209, 0001493152-25-023361 |
| Operating Margin | 7.21% | Operating Income / Revenue | OK | 0001493152-26-039209, 0001493152-25-023361 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-039209 |
| Current Ratio | 0.15x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.69 | Revenue / Diluted Shares | OK | 0001493152-26-039209, 0001493152-25-023361 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001493152-26-033207 |